BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
3110 results:

  • 1. GZ17-6.02 kills PDX isolates of uveal melanoma.
    Booth L; Roberts JL; Spasojevic I; Baker KC; Poklepovic A; West C; Kirkwood JM; Dent P
    Oncotarget; 2024 May; 15():328-344. PubMed ID: 38758815
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon pd-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
    Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
    Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Vaccimel immunization is associated with enhanced response to treatment with anti-pd-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
    Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
    Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Long-term survival after anti-pd-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
    Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
    Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma skin cancers.
    Ravipati A; Pradeep T; Nouri K
    J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
    Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
    In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
    Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.
    Qin L; Zhang G; Wu Y; Yang Y; Zou Z
    Cancer Immunol Immunother; 2024 Apr; 73(6):103. PubMed ID: 38630135
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Lifileucel: First Approval.
    Keam SJ
    Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginning.
    Wong MK; Yee C
    J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618960
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. T antigen-specific CD8+ T cells associate with pd-1 blockade response in virus-positive Merkel cell carcinoma.
    Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
    J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Melanoma neoantigen vaccines: Are we getting more personal now?
    Latifyan S; Haanen JB
    Med; 2024 Apr; 5(4):288-290. PubMed ID: 38614074
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-pd1 and Anti-CTLA4 Therapies.
    Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
    Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With pd-1 and PD-L1 Inhibitor Use.
    Aggarwal P; Clark D; Shah A; Rismiller K; Neltner SA
    JAMA Dermatol; 2024 May; 160(5):573-575. PubMed ID: 38598190
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant pd-1 inhibitors: a national cohort study.
    Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
    Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
    Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
    Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 156.